Optimizerx Corporation (OPRX)
NASDAQ (CM) NASDAQ (CM) Primary 
Can OptimizeRx's Cash Strength Cushion Near-Term Headwinds?
OPRX's rising cash flow, DAAP adoption and expanding pharma ties boost outlook despite near-term revenue softness and cautious client spending.
OPRX Trades at a Discount to Industry: How to Approach the Stock Now?
OptimizeRx trades at a steep discount to peers, but strong AI-driven growth, rising cash flow and DAAP traction look encouraging.
Should Value Investors Buy OptimizeRx (OPRX) Stock?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OPRX Cuts Revenue Outlook: Temporary Reset or Structural Concern?
OptimizeRx lowers 2026 revenue forecast on shifting pharma spend and managed services drag, but signals recovery ahead and stronger EBITDA expectations.
Are Investors Undervaluing OptimizeRx (OPRX) Right Now?
Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.
OptimizeRx (OPRX) Soars 5.9%: Is Further Upside Left in the Stock?
OptimizeRx (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corporation (OPRX) Q4 2025 Earnings Call Transcript
OptimizeRx Corp. (OPRX) Q4 Earnings and Revenues Beat Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.51 per share, beating the Zacks Consensus Estimate of $0.23 per share. This compares to earnings of $0.3 per share a year ago.
Strength Seen in OptimizeRx (OPRX): Can Its 7.5% Jump Turn into More Strength?
OptimizeRx (OPRX) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.
OptimizeRx Stock: A Buy-The-Dip Opportunity For This Above-Average Growth Story
OptimizeRx's Q3 2025 results reinforce my long-term bullish thesis. OPRX demonstrates continued operational momentum, supporting confidence in sustained growth. Recent earnings solidify conviction in the company's strategic positioning and execution.
OptimizeRx Corporation (OPRX) Q3 2025 Earnings Call Transcript
OptimizeRx Corporation ( OPRX ) Q3 2025 Earnings Call November 6, 2025 4:30 PM EST Company Participants Stephen Silvestro - President & CEO Edward Stelmakh - Chief Financial & Strategic Officer Andrew D'Silva - Chief Business Officer Conference Call Participants Ryan Daniels - William Blair & Company L.L.C., Research Division Richard Baldry - ROTH Capital Partners, LLC, Research Division David Grossman - Stifel, Nicolaus & Company, Incorporated, Research Division Eric Martinuzzi - Lake Street Capital Markets, LLC, Research Division Anderson Schock - B.
OptimizeRx Corp. (OPRX) Tops Q3 Earnings and Revenue Estimates
OptimizeRx Corp. (OPRX) came out with quarterly earnings of $0.2 per share, beating the Zacks Consensus Estimate of $0.03 per share. This compares to earnings of $0.12 per share a year ago.
